Sumit Sawhney
Overview
Dr. Sumit Sawhney is a board-certified hematologist and medical oncologist with more than 20 years of experience providing compassionate, patient-centered cancer care. He specializes in the diagnosis and treatment of a wide range of cancers and blood disorders, with particular expertise in lung cancer, lymphoma, and prostate cancer.
Dr. Sawhney earned his medical degree from University College of Medical Sciences, Delhi University, New Delhi, India, where he completed his medical training and developed a strong foundation in clinical medicine and oncology. He also attended St. Xavier's School in New Delhi, where he completed his undergraduate studies.
Throughout his career, Dr. Sawhney has been dedicated to delivering evidence-based, personalized treatment plans that address each patient's unique needs. He works closely with multidisciplinary care teams to provide comprehensive cancer care, guiding patients and their families through every stage of diagnosis, treatment, and survivorship.
Dr. Sawhney is affiliated with several leading hospitals in South Florida, including Broward Health Coral Springs and HCA Florida Northwest Hospital, and is recognized for his commitment to clinical excellence, innovation, and compassionate care.
Career positions
- Hematologist Oncologist | 1997 - Present
- President | Oncology and Hematologist Associates of West Broward | Coral Springs, FL
- Principal Investigator | SSAK Partners LLC, A Research Company | Coral Springs, FL
Clinical Interests
- Benign Hematology
- Malignant Hematology and Medical Oncology
Education
Universities
- M.D. | University College of Medical Sciences, New Delhi Medical School | New Delhi, India
- B.S. | St. Xavier's, New Delhi | New Delhi, India
Internship
- Rotatory Internship | Safdarjung Hospital, New Delhi | New Delhi, India
Residency
- Residency in Internal Medicine | University of Illinois | Chicago, IL
Fellowship
- Fellowship in Hematology-Oncology | University of Illinois | Chicago, IL
Expertise and interests
Board Certifications
- American Board of Medical Oncology
- American Board of Hematology
- American Board of Internal Medicine
Professional association
Awards and honors
- Chief of Staff | Northwest Medical Center | Margate, FL | 2021 - 2025
- Vice Chief of Staff Treasurer | Northwest Medical Center | Margate, FL | 2018 - 2020
- Chief of Medicine | Northwest Medical Center | Margate, FL | 2017 - 2018
- Vice Chief of Medicine | Northwest Medical Center | Margate, FL | 2014 - 2017
- House Officer on Duty | University of Illinois Hospital | Chicago, IL | 2012 - 2014
Clinical trials
- NAFTA Protocol | Breast Cancer
- LTS7072B-A Treatment Access Program with Oxaliplatin | Colorectal Cancer
- EFC 4585-A Irinotecan vs. Oxaliplatin + Irinotecan | Metastatic Colorectal Cancer
- EFC 4585-A 5-FU/LV ± Oxaliplatin Study | Metastatic Colorectal Cancer
- Protocol 401.00.001 PN401 vs. Gemcitabine | Pancreatic Cancer
- Protocol 440E-ONC-0020-262 CPT-11/Cisplatin vs. Cisplatin/Etoposide | Small Cell Lung Cancer
- NESP 20000220 Functional Capacity Screening Study | Chemotherapy-Induced Anemia
- AMGEN 20020132 Symptom Burden Study | Chemotherapy-Induced Anemia
- U23307 Rituxan + CHOP Followed by Maintenance Rituxan | Aggressive Lymphoma
- AMGEN 20020139 Darbepoetin Alfa Study | Chemotherapy-Induced Anemia
- CSMS995AUS38 Sandostatin LAR Depot Trial | Chemotherapy-Induced Diarrhea
- AMGEN 20030125 Darbepoetin Alfa vs. rHuEPO | Chemotherapy-Induced Anemia
- CPTAIV-0020-411 Fluoropyrimidine + Celecoxib vs. Placebo | Metastatic Colorectal Cancer
- OSI3199g Tarceva Trial | Non-Small Cell Lung Cancer
- ION-03-002 Modified FOLFOX6 + Cetuximab | Metastatic Colorectal Cancer
- ION-04-002 Cetuximab + Carboplatin + Docetaxel | Non-Small Cell Lung Cancer
- AMG 20030207 Darbepoetin Alfa Study | Myelodysplastic Syndrome
- AMG 20040262 Darbepoetin Alfa Dosing Study | Chemotherapy-Induced Anemia
- GENENTECH AVF3430g Avastin-Based First-Line Therapy Trial | Metastatic Colorectal Cancer
Research